MR Number;Product Name;Domain;Active substances;Pharmaceutical Form;Application Type Level 1;Application Type Level 2;Application Type Level 3;Application Type Level 4;Application Type Level 5;Marketing Authorization Holder;RMS;CMS;Date of outcome;Date of last update;ATC-Code;Strength;SPC Url;Par Url;Final Labelling Url;Final PL Url;Finalised Product Information Url
DK/H/0279/002 ;Daivobet;Human;"betamethasone dipropionate  0.5 mg/g, calcipotriol hydrate  50 µg/g";Gel;Line Extension;Initial Application;Fixed Combination;Chemical Substance;Prescription Only;LEO Pharma A/S Industriparken 55 2750 Ballerup Denmark;Denmark;AT - Daivobet 50 Mikrogramm/g + 0,5 mg/g Gel, BE, BG - Divobet gel, CY, CZ - Daivobet®, DE - Daivobet Kopfhaut - Gel 50 Mikrogramm / g + 0,5 mg/ g, EE, EL, ES, FI - Daivobet, FR, HU - Daivobet 50mcg/g + 5mg/g gél, IE, IS, IT, LT, LU, LV, MT - Daivobet® gel, NL, NO, PL, PT, RO - Daivobet® 50 micrograme/0,5 mg/g gel, SE - Daivobet, SI, SK, UK;15.08.2008;14.03.2013;D07XC01-Betamethasone;0.5mg/g;http://mri.medagencies.org/download/DK_H_0279_002_FinalSPC.pdf;http://www.hma.eu/fileadmin/dateien/pipar/dk279daivobet/parmod5_dk279daivobet.pdf;http://www.hma.eu/fileadmin/dateien/pipar/dk279daivobet/pllab_dk279daivobet.pdf;http://mri.medagencies.org/download/DK_H_0279_002_FinalPL.pdf;